Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C)

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.

A. Lok, L. Seeff, T. Morgan, et al.. (2009). Gastroenterology. Cited 645 times. https://doi.org/10.1053/j.gastro.2008.09.014

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

A. D. Di Bisceglie, M. Shiffman, G. Everson, et al.. (2008). The New England journal of medicine. Cited 593 times. https://doi.org/10.1056/NEJMoa0707615

Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.

A. Lok, R. Sterling, J. Everhart, et al.. (2010). Gastroenterology. Cited 521 times. https://doi.org/10.1053/j.gastro.2009.10.031

Outcome of sustained virological responders with histologically advanced chronic hepatitis C

T. Morgan, M. Ghany, Hae-Young Kim, et al.. (2010). Hepatology. Cited 510 times. https://doi.org/10.1002/hep.23744

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

M. Shiffman, A. D. Di Bisceglie, K. Lindsay, et al.. (2004). Gastroenterology. Cited 504 times. https://doi.org/10.1053/J.GASTRO.2004.01.014

Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.

L. Seeff, G. Everson, T. Morgan, et al.. (2010). Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Cited 450 times. https://doi.org/10.1016/j.cgh.2010.03.025

Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.

A. D. Di Bisceglie, R. Sterling, R. Chung, et al.. (2005). Journal of hepatology. Cited 371 times. https://doi.org/10.1016/J.JHEP.2005.03.019

Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT‐C cohort

A. Lok, M. Ghany, Z. Goodman, et al.. (2005). Hepatology. Cited 370 times. https://doi.org/10.1002/hep.20772

Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long‐term treatment against cirrhosis trial

J. Everhart, E. C. Wright, Z. Goodman, et al.. (2010). Hepatology. Cited 303 times. https://doi.org/10.1002/hep.23315

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT‐C trial

G. Everson, J. Hoefs, L. Seeff, et al.. (2006). Hepatology. Cited 289 times. https://doi.org/10.1002/hep.21440

Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.

H. Bonkovsky, K. K. Snow, P. Malet, et al.. (2007). Journal of hepatology. Cited 267 times. https://doi.org/10.1016/J.JHEP.2006.10.009

Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.

J. Everhart, A. Lok, Hae-Young Kim, et al.. (2009). Gastroenterology. Cited 262 times. https://doi.org/10.1053/j.gastro.2009.05.007

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C

J. Dienstag, M. Ghany, T. Morgan, et al.. (2011). Hepatology. Cited 250 times. https://doi.org/10.1002/hep.24370

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

M. Shiffman, M. Ghany, T. Morgan, et al.. (2007). Gastroenterology. Cited 214 times. https://doi.org/10.1053/J.GASTRO.2006.11.011

Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.

A. Lok, J. Everhart, E. Wright, et al.. (2011). Gastroenterology. Cited 192 times. https://doi.org/10.1053/j.gastro.2010.11.050

Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C

R. Fontana, Z. Goodman, J. Dienstag, et al.. (2008). Hepatology. Cited 189 times. https://doi.org/10.1002/hep.22099

Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.

William M. Lee, J. Dienstag, K. Lindsay, et al.. (2004). Controlled clinical trials. Cited 183 times. https://doi.org/10.1016/J.CCT.2004.08.003

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C

N. Freedman, J. Everhart, K. Lindsay, et al.. (2009). Hepatology. Cited 176 times. https://doi.org/10.1002/hep.23162

Herbal product use by persons enrolled in the hepatitis C Antiviral Long‐Term Treatment Against Cirrhosis (HALT‐C) Trial

L. Seeff, T. Curto, G. Szabo, et al.. (2007). Hepatology. Cited 149 times. https://doi.org/10.1002/hep.22044

A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

Barham K. Abu Dayyeh, May H. Yang, B. Fuchs, et al.. (2011). Gastroenterology. Cited 144 times. https://doi.org/10.1053/j.gastro.2011.03.045

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C

R. Fontana, J. Dienstag, H. Bonkovsky, et al.. (2010). Gut. Cited 105 times. https://doi.org/10.1136/gut.2010.207423

The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.

A. Sanyal, R. Fontana, A. D. Di Bisceglie, et al.. (2006). Gastrointestinal endoscopy. Cited 104 times. https://doi.org/10.1016/J.GIE.2006.03.007

Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.

M. Ghany, A. Lok, J. Everhart, et al.. (2010). Gastroenterology. Cited 100 times. https://doi.org/10.1053/j.gastro.2009.09.007

Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C

A. Lok, J. Everhart, A. D. Di Bisceglie, et al.. (2011). Hepatology. Cited 98 times. https://doi.org/10.1002/hep.24257

Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.

H. Bonkovsky, D. Naishadham, R. Lambrecht, et al.. (2006). Gastroenterology. Cited 97 times. https://doi.org/10.1053/J.GASTRO.2006.08.036

Silymarin use and liver disease progression in the Hepatitis C Antiviral Long‐Term Treatment against Cirrhosis trial

N. Freedman, T. Curto, C. Morishima, et al.. (2011). Alimentary Pharmacology & Therapeutics. Cited 83 times. https://doi.org/10.1111/j.1365-2036.2010.04503.x

Variants in interferon‐alpha pathway genes and response to pegylated interferon‐Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long‐term treatment against cirrhosis trial

T. Welzel, T. Morgan, H. Bonkovsky, et al.. (2009). Hepatology. Cited 80 times. https://doi.org/10.1002/hep.22877

Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial.

R. Fontana, L. Bieliauskas, Carla Back-Madruga, et al.. (2005). Journal of hepatology. Cited 77 times. https://doi.org/10.1016/J.JHEP.2005.04.006

Portal Hypertensive Gastropathy in Chronic Hepatitis C Patients with Bridging Fibrosis and Compensated Cirrhosis: Results from the HALT-C Trial

R. Fontana, A. Sanyal, S. Mehta, et al.. (2006). The American Journal of Gastroenterology. Cited 77 times. https://doi.org/10.1111/j.1572-0241.2006.00461.x

Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT‐C trial

Z. Goodman, A. Stoddard, H. Bonkovsky, et al.. (2009). Hepatology. Cited 74 times. https://doi.org/10.1002/hep.23211

Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.

R. Lambrecht, R. Sterling, D. Naishadham, et al.. (2011). Gastroenterology. Cited 73 times. https://doi.org/10.1053/j.gastro.2011.01.053

Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long‐term treatment against cirrhosis trial

G. Everson, M. Shiffman, J. Hoefs, et al.. (2012). Hepatology. Cited 73 times. https://doi.org/10.1002/hep.24752

Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.

N. Freedman, T. Curto, K. Lindsay, et al.. (2011). Gastroenterology. Cited 71 times. https://doi.org/10.1053/j.gastro.2011.02.061

Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.

R. Fontana, A. Sanyal, M. Ghany, et al.. (2010). Gastroenterology. Cited 66 times. https://doi.org/10.1053/j.gastro.2010.02.058

The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort

Barham K. Abu Dayyeh, May H. Yang, J. Dienstag, et al.. (2011). Digestive Diseases and Sciences. Cited 61 times. https://doi.org/10.1007/s10620-010-1507-8

Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long‐term treatment against cirrhosis (HALT‐C) trial

A. Lok, J. Everhart, R. Chung, et al.. (2009). Hepatology. Cited 58 times. https://doi.org/10.1002/hep.22865

Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.

C. Morishima, S. Polyak, R. Ray, et al.. (2006). The Journal of infectious diseases. Cited 57 times. https://doi.org/10.1086/500952

DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial.

T. Morgan, R. Lambrecht, H. Bonkovsky, et al.. (2008). Journal of hepatology. Cited 51 times. https://doi.org/10.1016/j.jhep.2008.05.011

HCV RNA detection by TMA during the hepatitis C antiviral long‐term treatment against cirrhosis (Halt‐C) trial

C. Morishima, T. Morgan, J. Everhart, et al.. (2006). Hepatology. Cited 50 times. https://doi.org/10.1002/hep.21265

Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.

R. Fontana, H. Bonkovsky, D. Naishadham, et al.. (2009). Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Cited 50 times. https://doi.org/10.1016/j.cgh.2008.10.034

Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.

A. Lok, J. Everhart, R. Chung, et al.. (2007). Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Cited 47 times. https://doi.org/10.1016/J.CGH.2006.11.002

Changes in Mood States and Biomarkers During Peginterferon and Ribavirin Treatment of Chronic Hepatitis C

R. Fontana, Z. Kronfol, K. Lindsay, et al.. (2008). The American Journal of Gastroenterology. Cited 46 times. https://doi.org/10.1111/j.1572-0241.2008.02106.x

The complete mitochondrial genome of bighead croaker, Collichthys niveatus (Perciformes, Sciaenidae): structure of control region and phylogenetic considerations

Tianjun Xu, Yuan-zhi Cheng, Yueyan Sun, et al.. (2011). Molecular Biology Reports. Cited 45 times. https://doi.org/10.1007/s11033-010-0602-4

Excess mortality in patients with advanced chronic hepatitis C treated with long‐term peginterferon

A. D. Di Bisceglie, A. Stoddard, J. Dienstag, et al.. (2011). Hepatology. Cited 44 times. https://doi.org/10.1002/hep.24169

Serum Vitamin D Levels Are Not Predictive of the Progression of Chronic Liver Disease in Hepatitis C Patients with Advanced Fibrosis

K. Corey, Hui Zheng, J. Mendez-Navarro, et al.. (2012). PLoS ONE. Cited 43 times. https://doi.org/10.1371/journal.pone.0027144

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C

R. Fontana, L. Bieliauskas, K. Lindsay, et al.. (2007). Hepatology. Cited 41 times. https://doi.org/10.1002/hep.21633

Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C

A. Rothman, C. Morishima, H. Bonkovsky, et al.. (2005). Hepatology. Cited 39 times. https://doi.org/10.1002/hep.20581

Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.

M. Shiffman, C. Morishima, J. Dienstag, et al.. (2009). Gastroenterology. Cited 38 times. https://doi.org/10.1053/j.gastro.2009.08.067

Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.

J. Hoefs, M. Shiffman, Z. Goodman, et al.. (2011). Gastroenterology. Cited 38 times. https://doi.org/10.1053/j.gastro.2011.06.007

Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT‐C trial

G. Everson, M. Shiffman, J. Hoefs, et al.. (2009). Alimentary Pharmacology & Therapeutics. Cited 35 times. https://doi.org/10.1111/j.1365-2036.2008.03908.x

Predicting clinical outcomes using baseline and follow‐up laboratory data from the hepatitis C long‐term treatment against cirrhosis trial

M. Ghany, Hae-Young Kim, A. Stoddard, et al.. (2011). Hepatology. Cited 33 times. https://doi.org/10.1002/hep.24550

The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti‐viral Long‐term Treatment against Cirrhosis Trial 1

G. Everson, M. Shiffman, T. Morgan, et al.. (2008). Alimentary Pharmacology & Therapeutics. Cited 32 times. https://doi.org/10.1111/j.1365-2036.2008.03639.x

A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment.

Amira Pierucci-Lagha, J. Covault, H. Bonkovsky, et al.. (2010). Psychosomatics. Cited 32 times. https://doi.org/10.1176/appi.psy.51.2.137

Strengths and Limitations of Commercial Tests for Hepatitis C Virus RNA Quantification

C. Morishima, M. Chung, K. Ng, et al.. (2004). Journal of Clinical Microbiology. Cited 31 times. https://doi.org/10.1128/JCM.42.1.421-425.2004

Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.

K. Lindsay, C. Morishima, E. Wright, et al.. (2008). Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Cited 30 times. https://doi.org/10.1016/j.cgh.2007.11.020

An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C

T. O'Brien, J. Everhart, T. Morgan, et al.. (2011). PLoS ONE. Cited 29 times. https://doi.org/10.1371/journal.pone.0020904

Changes in quality of life and sexual health are associated with low‐dose peginterferon therapy and disease progression in patients with chronic hepatitis C

K. K. Snow, H. Bonkovsky, R. Fontana, et al.. (2010). Alimentary Pharmacology & Therapeutics. Cited 28 times. https://doi.org/10.1111/j.1365-2036.2010.04235.x

Portal‐systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt

G. Everson, Michael A. Martucci, M. Shiffman, et al.. (2007). Alimentary Pharmacology & Therapeutics. Cited 27 times. https://doi.org/10.1111/j.1365-2036.2007.03389.x

Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C.

M. Rakoski, Morton B. Brown, R. Fontana, et al.. (2011). Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Cited 26 times. https://doi.org/10.1016/j.cgh.2011.07.006

Clinical Relevance of Cognitive Scores in Hepatitis C Patients with Advanced Fibrosis

L. Bieliauskas, Carla Back-Madruga, K. Lindsay, et al.. (2006). Journal of Clinical and Experimental Neuropsychology. Cited 25 times. https://doi.org/10.1080/13803390500473720

Interpretation of positive transcription‐mediated amplification test results from polymerase chain reaction–negative samples obtained after treatment of chronic hepatitis C

C. Morishima, T. Morgan, J. Everhart, et al.. (2008). Hepatology. Cited 25 times. https://doi.org/10.1002/hep.22487

Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7)

T. Curto, R. Lagier, A. Lok, et al.. (2011). Pharmacogenetics and Genomics. Cited 24 times. https://doi.org/10.1097/FPC.0b013e32834c3e74

Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy *

H. Yuan, M. Jain, K. K. Snow, et al.. (2010). Journal of Viral Hepatitis. Cited 23 times. https://doi.org/10.1111/j.1365-2893.2009.01169.x

YKL‐40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C

R. Fontana, H. Litman, J. Dienstag, et al.. (2012). Liver International. Cited 22 times. https://doi.org/10.1111/j.1478-3231.2011.02686.x

Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C

L. Bieliauskas, Carla Back-Madruga, K. Lindsay, et al.. (2007). Journal of the International Neuropsychological Society. Cited 21 times. https://doi.org/10.1017/S1355617707070877

Development and Progression of Portal Hypertensive Gastropathy in Patients With Chronic Hepatitis C

R. Fontana, A. Sanyal, M. Ghany, et al.. (2011). The American Journal of Gastroenterology. Cited 21 times. https://doi.org/10.1038/ajg.2010.456

Extended Interferon-Alpha Therapy Accelerates Telomere Length Loss in Human Peripheral Blood T Lymphocytes

Joel M. O'Bryan, James A. Potts, H. Bonkovsky, et al.. (2011). PLoS ONE. Cited 21 times. https://doi.org/10.1371/journal.pone.0020922

Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C

C. Morishima, M. Shiffman, J. Dienstag, et al.. (2012). The American Journal of Gastroenterology. Cited 16 times. https://doi.org/10.1038/ajg.2012.137

Cognitive Function Does Not Worsen During Long-Term Low-Dose Peginterferon Therapy in Patients With Chronic Hepatitis C

R. Fontana, L. Bieliauskas, Carla Back-Madruga, et al.. (2010). The American Journal of Gastroenterology. Cited 15 times. https://doi.org/10.1038/ajg.2010.3

Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis

S. Polyak, D. Sullivan, Michael Austin, et al.. (2005). Virology Journal. Cited 11 times. https://doi.org/10.1186/1743-422X-2-41

Antigen‐specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C

C. Morishima, A. D. Di Bisceglie, A. Rothman, et al.. (2012). Journal of Viral Hepatitis. Cited 11 times. https://doi.org/10.1111/j.1365-2893.2011.01562.x

No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.

Z. Kronfol, H. Litman, Carla Back-Madruga, et al.. (2011). Journal of affective disorders. Cited 4 times. https://doi.org/10.1016/j.jad.2010.09.010

Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial

Margaret C. Bell, Patricia R. Robuck, E. Wright, et al.. (2009). Clinical Trials. Cited 3 times. https://doi.org/10.1177/1740774509348525